MOH — authorised 26 February 2021
- Marketing authorisation holder: ORIGIN
- Status: likely_approved
MOH authorised Nulibry on 26 February 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 26 February 2021.
ORIGIN holds the Israeli marketing authorisation.